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Edited by Jesus AvilaAbstract Increasing evidence suggests that an inhibition of the
proteasome, as demonstrated in Parkinsons disease, might be in-
volved in Alzheimers disease. In this disease and other Tauopa-
thies, Tau proteins are hyperphosphorylated and aggregated
within degenerating neurons. In this state, Tau is also ubiquiti-
nated, suggesting that the proteasome might be involved in Tau
proteolysis. Thus, to investigate if proteasome inhibition leads
to accumulation, hyperphosphorylation and aggregation of
Tau, we used neuroblastoma cells overexpressing Tau proteins.
Surprisingly, we showed that the inhibition of the proteasome
led to a bidirectional degradation of Tau. Following this result,
the cellular mechanisms that may degrade Tau were investigated.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A large number of neurodegenerative disorders are charac-
terized by intracellular protein aggregates. In Tauopathies,
such deposits within neurons are composed of hyperphosph-
orylated Tau proteins. The knowledge for this abnormal ﬁbril-
logenesis of Tau is not completely understood despite that
much evidence suggests an hyperphosphorylation of these pro-
teins before their pathological aggregation [1]. In neurons,
accumulation of Tau proteins in the cytoplasm may also in-
duce their hyperphosphorylation and aggregation [2,3]. Tau
proteins are substrates for many intracellular proteases,
including caspases, calpain 1 and the proteasome. Inhibition
of one of these proteolytic systems could lead to the intraneu-
ronal accumulation of Tau proteins.
Tau proteins were shown to be sensitive to calpain degra-
dation [4]. This protease, together with its inhibitor, calpast-
atin, makes up a complex that is thought to be involved in
the synaptic impairment of Alzheimers disease (AD) [5–7].
In apoptotic cells, it was also shown that the degradation
of Tau is related to caspase activation [8–10]. The cleavage
generates Tau fragments turning Tau itself into an eﬀectorAbbreviations: AD, Alzheimers disease; GSK3b, glycogen synthase
kinase 3 beta; PARP, poly-(ADP-ribose)-polymerase; SDS–PAGE,
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2004.11.018of apoptosis [10,11]. This Tau proteolysis may precede ﬁla-
mentous deposits of Tau within degenerating neurons, which
then may participate in the progression of neuronal cell death
in AD.
These data indicate that diﬀerent proteolytic systems could
be involved in Tau proteolysis and presumably in Alzhei-
mers pathology. However, the least documented is the pro-
teasome system. Basically, in Alzheimers or Parkinsons
disease, it was eﬀectively shown that proteasome activity
was inhibited [12–14]. In Tauopathies, Tau proteins are
hyperphosphorylated and ubiquitinated [1], suggesting that
proteasome activity may be implicated in Tau proteolysis
within neurons under normal and physiological conditions.
Furthermore, in vitro experiments demonstrated the prote-
asomal-dependent degradation of Tau [15]. It was recently
shown that an inhibition of proteasome activity may con-
tribute to the stabilization of aggregates made by hyper-
phosphorylated Tau in oligodendroglial cells [16]. Despite
these observations, the real impact of proteasome inhibition
on Tau protein catabolism in neuronal cells remains to be
elucidated.
Thus, to test the relationship between Tau proteolysis and
proteasome activity in neurons, proteasomal activity was selec-
tively inhibited in neuroblastoma cell lines overexpressing Tau
proteins. Surprisingly, we showed that in contrast to in vitro
experiments, the inhibition of the proteasome led to Tau pro-
teolysis within cells. Following these results, we then investi-
gated which proteolytic processes might be involved in this
phenomenon.2. Materials and methods
2.1. Antibodies
Phosphorylation-dependent Tau monoclonal antibodies include
AD2 directed against phosphorylated Ser396–404 [17], AT270 recog-
nizing phosphorylated Thr 181 [18] and Tau-1 that binds amino-
acids 189–207 only when they are dephosphorylated [19]. Abnormal
phosphorylation of Tau was assessed with AT100 and AP422 (rec-
ognizing phosphorylated T212/S214 and S422, respectively). M19G
and Tau-Cter are well characterized antisera, directed against the
ﬁrst 19 amino acids of the Tau sequence [17] and the carboxy-termi-
nal fragment of Tau (last 15 amino acids), respectively [20]. They
both recognize their epitope independently of the Tau phosphoryla-
tion state (Fig. 1A).
b-Catenin quantities were determined using the anti-b-catenin H102.
Calpain and its inhibitor protein Calpastatin were detected using the
anti-calpain1 N19 and anti-calpastatin C19 antibodies (Santa Cruz
Biotechnology). Poly-(ADP-ribose)-polymerase (PARP) cleavage was
visualized using an Anti-Poly-(ADP-Ribose)-Polymerase antibody
(Roche Molecular Biochemical, Mannheim, Germany) and reﬂected
caspase activity. When caspases are activated, the 113 kDa PARP
holoprotein is cleaved into 89 and 24 kDa fragments, which couldblished by Elsevier B.V. All rights reserved.
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phosphate dehydrogenase (GAPDH) was detected using the anti-
GAPDH FL-335 (Santa Cruz Biotechnology).
2.2. Cell culture
Stably transfected SY5Y neuroblastoma cells were generated as de-
scribed earlier [21,22]. Cells were grown in 25 cm2 ﬂasks in Dulbeccos
modiﬁed Eagles medium supplemented with 10% (v/v) fetal calf serum,
2 mM L-glutamine, 1 mM non-essential amino-acids and penicillin/streptomycin (Invitrogen SARL, Cergy Pontoise, France) supple-
mented with G418 (Invitrogen SARL) in a 5% CO2 humidiﬁed incuba-
tor at 37 C.
2.3. Cell treatments and lysates
Protein translation was inhibited by cycloheximide (50 lg/ml) (Sig-
ma–Aldrich SARL, Lisle dAbeau Chesne, France), as described in
[15]. LiCl (10 mM) was used to inhibit glycogen synthase kinase 3 beta
(GSK3b) [23]. Lactacystin (10 lM), Proteasome inhibitor (PSI) (10
and 100 lM) and MG132 (40 nM, 200 nM, 3 lM and 10 lM) were
used to inhibit ubiquitin-independent (20S) or dependent (26S) protea-
some activities, respectively (Calbiochem, Merck Eurolab, Fontenay-
sous-bois, France). ALLN (200 nM) (Calbiochem) and Caspase
inhibitor Z-VAD-FMK (50 lM) (Promega, USA) were used for inhib-
iting calpain and caspase activities, respectively. All treatments were
done three times in independent experiments.
After each treatment, samples were prepared for biochemical analy-
ses as previously described [22]. Protein concentrations were estimated
by the BCA protein assay kit (Pierce) and were adjusted at 1 lg/ll.
Proteins were then separated on 10% or 15% sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE), transferred
and visualized as described previously [3,22].3. Results
3.1. Tau protein proteolysis after proteasome inhibition
A neuroblastoma cell line SY5Y overexpressing 3R Tau was
used to investigate the implication of the proteasome on Tau
proteolysis. The proteasome was inhibited by diﬀerent drugs,
including PSI, MG132 (Fig. 1B) and lactacystin (data not
shown). b-Catenin was used as a control of proteasome inhibi-
tion. Indeed, this protein was shown to be degraded speciﬁcally
by the proteasome after its prephosphorylation by GSK3b
[24,25]. After proteasome inhibition, b-catenin amounts were
increased (Fig. 1B) suggesting that under our conditions, the
proteasome was eﬃciently inactivated. This result was also
conﬁrmed by the use of cycloheximide (CHX), a translation
inhibitor. As expected, by application of CHX, a 50% loss of
b-catenin immunoreactivity was observed after 16 h (Fig.
1B). This loss was prevented if CHX was used in the presence
of lithium (GSK3b inhibitor), suggesting that in our model
GSK3b targets the b-catenin to the proteasome, as describedFig. 1. (A) Schematic representation of anti-Tau antibodies used in the
study. M19G and Tau-Cter recognize Tau proteins independently of
their phosphorylation state (N and C terminal epitopes, respectively).
Three diﬀerent antibodies were also used to analyze the normal
phosphorylation state of Tau (AT270, Tau-1 and AD2). Finally, the
abnormal phosphorylation of Tau was assessed with AT100 and
AP422 antibodies [22]. (B) Eﬀect of proteasome and/or translation
inhibition on b-catenin levels. The translation was inhibited by
cycloheximide (CHX, 50 lg/ml). PSI and MG132 (10 lM and 200
nM) were used to inhibit proteasome acivity. These inhibitors were
used alone or in combination during a time course experiment (4, 8, 16
and 24 h). Note that similar amounts of total proteins were loaded
after each treatment. Immunoreactivities obtained after Western
Blotting were measured and reported on the relative percentage of b-
catenin observed in untreated cells (To). (C) Tau protein degradation
and phosphorylation analysis after translation and/or proteasome
inhibition. Tau protein degradation and phosphorylation were ana-
lyzed for 4, 8, 16 and 24 h after translation (CHX, 50 lg/ml) and/or
proteasome (PSI, 10 lM or MG132, 200 nM) inhibition. Immunore-
activities for TauCter, M19G, AT270 and Tau-1, obtained after
Western blotting, were quantiﬁed and reported on the relative
percentage observed in untreated cells (To). It is of note that the
same amount of total protein was loaded for each experiment as
demonstrated by the Western blot showing GAPDH.
b
Fig. 2. (A) Tau protease expression after the inhibition of the
proteasome. After inhibition of the proteasome and/or the translation
for 24 h (same experimental procedures as described for Fig. 1), the
amounts of Tau proteases or activity were determined by immuno-
blotting. Caspase activity was estimated by following PARP cleavage
(89 kDa). Calpain I and calpastatin (calpain intracellular inhibitor)
amounts were detected directly. Each immunoreactivity was compared
to those obtained for untreated cells (To). (B) Tau protease inhibition
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(proteasome inhibitors/CHX) showed no modiﬁcation in cellu-
lar quantities of b-catenin, indicating that this protein is
mainly proteolyzed through the proteasome pathway.
Conversely to b-catenin, 8 h after the addition of the protea-
some inhibitors, Tau proteolysis was observed (Fig. 1C, PSI
and MG132). This catabolism of Tau was bidirectional since
the loss of Tau-immunoreactivities, obtained with M19G and
Tau Ct antibodies, was similar (Fig. 1C, histograms). Under
CHX conditions, Tau protein amounts appeared to be in-
creased (Fig. 1C). Tau seems then to be more stable than other
intracellular proteins such as b-catenin. When we combined
translation and proteasome inhibitors, we also showed that
Tau proteolysis was prevented. This result suggested that
newly synthesized proteins such as proteases might be impli-
cated in proteolysis of Tau after proteasome inhibition.
As a control, the same set of experiments was performed in
native neuroblastoma cells. Treatment of these cells with
MG132 (40, 200 nM, 3 and 10 lM) for 24 h showed similar re-
sults to those obtained with the neuroblastoma cell line over-
expressing Tau proteins, i.e., a loss in Tau immunoreactivity
(data no shown). All these results suggested that the loss of
Tau proteins is subsequent to proteasome inhibition in neuro-
blastoma cell lines.assessment during proteasome inactivation. Calpain was inactivated by
ALLN, caspases by the caspase inhibitor Z-VAD-FMK and lysosomal
activity by NH4Cl or Chloroquine (data not shown). Caspase activity
during each treatment was estimated using an Anti-PARP antibody.
Tau protein proteolysis was measured for 24 h by M19G and Tau Cter
polyclonal antibodies.3.2. Tau protein phosphorylation and proteolysis
It was recently shown that many proteins could be tar-
geted towards the proteasome only if they were previously
hyperphosphorylated at many sites [24–26]. Moreover, in
Tauopathies, Tau proteins are hyperphosphorylated and
aggregated within neurons. In our system, overexpression
of Tau proteins leads to their hyperphosphorylation [3,22].
Thus, to investigate if the phosphorylation of Tau is impli-
cated in its degradation, the phosphorylation state of Tau
was studied using ﬁve phosphorylation-dependent antibodies
(Fig. 1A) after proteasome and/or translation inhibition. As
detected by biochemical experiments, Tau phosphorylation
was not aﬀected after proteasome or translation inhibition.
Indeed, similar immunoreactivity proﬁles were obtained with
phosphorylation dependent antibodies (AD2, AT270 and
Tau-1) as compared to M19G or Tau-Cter (Fig. 1C, histo-
grams). Moreover, no abnormal phosphorylation of Tau
proteins was detected after each treatment (data not shown).
These data indicated that during all these treatments, no
changes in Tau phosphorylation occurred. It is of note that
the use of phosphorylation-dependent antibodies reinforced
the idea that during proteasomal inhibition, Tau proteins
were degraded from their C-terminal and N-terminal extrem-
ities, since the same proteolysis proﬁles were obtained with
all Tau dependent antibodies (Fig. 1C, histograms).3.3. Tau protease induction after proteasome inhibition
The previous experiments showed that after proteasome
inhibition, Tau proteins were degraded only if translation
was not prevented. This suggested that a protein synthesis or
an indirect activation of proteases might be required for Tau
proteolysis after proteasome inhibition. To test this hypothe-
sis, we investigated caspase activity by following PARP cleav-
age, the intracellular levels of calpain I, and its inhibitor
calpastatin. Regarding PARP cleavage, caspase activity was
more important after CHX treatments (alone or in combina-tion with proteasome inhibitors) than when only the protea-
some was inhibited (Fig. 2A, PARP). This suggested that
caspases were activated after CHX treatment even if no prote-
olysis of Tau was evident. Conversely, proteasome inhibition
led to calpain I accumulation and calpastatin degradation in
cells after 8 h (Fig. 2A, panels PSI and MG132). It is of note
that Tau protein proteolysis is concomitant with the induction
of calpain and the loss of calpastatin (compare Fig. 1C and
2A). Under CHX conditions, a relative increase in calpastatin
immunoreactivity was observed, indicating that under these
conditions calpastatin was relatively stable. These data indi-
cated that the proteasome may be implicated directly or indi-
rectly in the degradation of calpastatin in cells, thereby
regulating the calpain I activity.
Finally, in order to investigate the impact of these proteo-
lytic systems on Tau catabolism when the proteasome was
inactivated, speciﬁc inhibitors (ALLN (200 nM) for calpain
and caspase inhibitor Z-VAD-FMK (50 lM)) were used. Bio-
chemical analyses showed that only a co-treatment of protea-
some inhibitors with ALLN reduced the loss of Tau proteins
(Fig. 2B). In contrast, when caspase activity was inactivated
during the same time as the proteasome, no change in Tau
degradation was seen even if a delay in PARP cleavage was
observed.
Taken together, these results suggested that ﬁrst caspases
may not be involved in Tau proteolysis after inhibition of
the proteasome. Second, proteasome inhibition led to calpain
I stability or synthesis. Third, proteasome inhibition led also
to calpastatin proteolysis. This degradation seemed to be indi-
rect and dependent on newly synthetized protein, since calpast-
























Fig. 3. Schematic representation of Tau proteolysis after proteasome
inhibition or induced apoptosis. Proteasome inhibition may lead to
calpain activation by decreasing calpastatin levels. This eﬀect is
indirect, since the use of cycloheximide inhibits calpastatin degrada-
tion. Therefore, some other proteases and/or chaperone proteins may
be necessary to inactivate or degrade calpastatin protein. Once calpain
is activated, Tau proteins are degraded by a bidirectional process.
Under apoptotic conditions, caspases are activated and cleaved Tau by
a monodirectional process that begins at their C-terminal extremity [3].
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We have analyzed the implication of proteasome activity in
Tau proteolysis in neuroblastoma cell lines and demonstrated
that after proteasome inhibition, Tau proteins are catabolized
by a bidirectional process, which is protein-translation-depen-
dent. These data also argued that this Tau degradation is inde-
pendent of its normal and physiological phosphorylation state.
How can we explain the results observed in our cell system,
since the proteasome seems to be implicated directly in Tau
degradation in vitro [15]? In fact, the proteasome is a general
degradation system that could act on proteins directly impli-
cated in Tau proteolysis or phosphorylation. Concerning
Tau proteases, the proteasome can work on their expression
or activity in function of cell type and cell metabolism.
Depending on the cell system, the proteasome may lead to
an overexpression of caspases or calpain and could therefore
act indirectly on Tau protein catabolism. In our system, cal-
pain accumulated after proteasome inhibition while its cellular
inhibitor calpastatin was degraded. Thus, if the proteasome is
not functional under these conditions, calpain is activated and
therefore Tau proteins can be proteolyzed by a bidirectional
process (Fig. 3). This eﬀect is not direct and requires presum-
ably protein synthesis, since the Tau proteolysis was not in-
duced if translation was inhibited.
In this study, we also demonstrated that proteasome inhibi-
tion did not lead to apoptosis and that caspases seemed unli-
kely to be involved in Tau degradation under this condition.
Indeed, in this cell system, caspase activation leads to a mono-
directional (carboxy-terminal) degradation of Tau and not
bidirectional as observed after MG132 or PSI treatments [3].
Moreover, one of the most characteristic sign of neuronal
apoptosis is the formation of a dephosphorylated Tau frag-
ment of 17 kDa that can be visualized with Tau-1 antibody[8]. As this fragment never appeared after MG132 or PSI treat-
ments and as a delayed PARP cleavage was seen, it seems
therefore that Tau proteolysis is not associated with caspase
activity after proteasome inhibition. Finally, it is also of note
that Tau protein might also be a substrate for lysosomal pro-
teins such as Cathepsin D [27]. However, it seems that this
pathway is not involved in Tau proteolysis after proteasome
inhibition, since a co-treatment with MG132 and NH4Cl or
Chloroquine (two lysosomal activity inhibitors) failed to re-
duce the degradation of Tau (data not shown).5. Conclusion
We demonstrated that proteasome inhibition, in neuroblas-
toma cell lines, leads to the degradation of Tau proteins by a
bidirectional process that involves presumably the calpain/
calpastatin system. This study also suggests that under phys-
iological conditions where Tau proteins are normally phos-
phorylated, the proteasome inhibition does not lead to Tau
protein hyperphosphorylation or aggregation but to its degra-
dation. Finally, we demonstrated for the ﬁrst time that pro-
teasome inhibition could be involved in calpain activation
within neurons by altering calpastatin levels. This inhibition
could be implicated in neurodegenerative process progression
in Tauopathies where calpain was shown to be overactivated.
Therefore, calpain activation in AD might not only be depen-
dent on the. excitotoxicity or amyloid-beta exposure. This
could be an alternative mechanism by which therapeutic ap-
proaches could be generated.
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